Table 3.

Multivariable-adjusted associations for combined PCPT treatment arms of serum 25(OH)D concentrations and prostate cancer risk in the PCPT by age and BMI

	All cancer		Gleason 2–6		Gleason 7		Gleason 8–10
	Case/control	OR^a (95% CI)	Case/control	OR^a (95% CI)	Case/control	OR^a (95% CI)	Case/control	OR^a (95% CI)
Age, y
<65
Q1^b	213/260	Ref	139/260	Ref	47/260	Ref	20/260	Ref
Q2^b	243/247	1.02 (0.78–1.33)	174/247	1.11 (0.82–1.48)	44/247	0.86 (0.55–1.36)	18/247	0.87 (0.44–1.71)
Q3^b	256/253	1.01 (0.77–1.32)	188/253	1.12 (0.83–1.50)	43/253	0.80 (0.50–1.27)	14/253	0.65 (0.31–1.36)
Q4^b	288/231	1.16 (0.89–1.52)	207/231	1.26 (0.94–1.68)	58/231	1.11 (0.72–1.73)	15/231	0.73 (0.35–1.51)
		0.28		0.15		0.65		0.30
65+
Q1^b	145/161	Ref	86/161	Ref	32/161	Ref	20/161	Ref
Q2^b	151/173	0.89 (0.64–1.22)	92/173	0.87 (0.60–1.27)	36/173	1.02 (0.60–1.74)	12/173	0.56 (0.27–1.20)
Q3^b	193/166	1.15 (0.84–1.57)	116/166	1.12 (0.78–1.61)	48/166	1.35 (0.82–2.25)	18/166	0.85 (0.43–1.69)
Q4^b	206/191	1.03 (0.76–1.41)	139/191	1.14 (0.80–1.62)	46/191	1.09 (0.66–1.81)	10/191	0.40 (0.18–0.88)
		0.47		0.22		0.55		0.07
P_interaction		0.80		0.99		0.99		0.52
BMI^c
<25
Q1^b	66/94	Ref	47/94	Ref	10/94	Ref	7/94	Ref
Q2^b	95/81	1.33 (0.84–2.09)	71/81	1.34 (0.81–2.20)	18/81	1.88 (0.81–4.37)	4/81	0.59 (0.16–2.15)
Q3^b	145/110	1.49 (0.97–2.27)	101/110	1.39 (0.87–2.23)	26/110	1.96 (0.88–4.37)	8/110	0.81 (0.27–2.39)
Q4^b	176/149	1.26 (0.84–1.90)	122/149	1.18 (0.76–1.86)	40/149	2.13 (0.99–4.59)	8/149	0.54 (0.18–1.59)
		0.79		0.66		0.08		0.34
25–<30
Q1^b	172/200	Ref	104/200	Ref	43/200	Ref	17/200	Ref
Q2^b	212/225	0.99 (0.75–1.32)	140/225	1.07 (0.77–1.48)	41/225	0.78 (0.48–1.25)	19/225	1.00 (0.50–2.01)
Q3^b	220/230	0.95 (0.72–1.27)	149/230	1.06 (0.77–1.47)	45/230	0.78 (0.49–1.25)	17/230	0.85 (0.41–1.74)
Q4^b	258/225	1.11 (0.84–1.48)	188/225	1.33 (0.97–1.82)	48/225	0.83 (0.52–1.33)	12/225	0.60 (0.23–1.31)
		0.47		0.08		0.51		0.18
30+
Q1^b	120/127	Ref	74/127	Ref	26/127	Ref	16/127	Ref
Q2^b	87/114	0.71 (0.48–1.05)	55/114	0.71 (0.45–1.11)	21/114	0.83 (0.44–1.58)	7/114	0.46 (0.18–1.17)
Q3^b	84/79	1.00 (0.66–1.51)	54/79	1.00 (0.63–1.60)	20/79	1.16 (0.60–2.27)	7/79	0.66 (0.25–1.73)
Q4^b	60/48	1.02 (0.64–1.64)	36/48	0.97 (0.57–1.66)	16/48	1.32 (0.63–2.73)	5/48	0.69 (0.23–2.05)
		0.76		0.89		0.37		0.44
P_interaction^d		0.47		0.41		0.28		0.61

NOTE: Vitamin D standardized for month of blood draw before dividing into quartiles based on distribution in controls.

↵^aORs adjusted for age (except age-stratified models), race (White, African American, other race), and treatment (finasteride, placebo).
↵^bQuartile cutoff points based on the distribution in controls in each strata.
↵^cThirty-three men missing BMI data were not included in BMI stratified analyses.
↵^dInteraction tested as the cross-product of 25(OH)D concentration rank (lowest to highest quartile) and an indicator for age (<65, ≥65) or BMI (<25, 25–<30, ≥30).